URMC / Research / Clinical Trials / Study Details

ULYM18086 / acalabrutinib -Barr IIT / Paul Barr

Research Question:
Is the combination of the drug acalabrutinib and antibody therapy, rituximab, safe and effective in patients who have previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)?

Basic Study Information

Purpose:
The main purpose of this research study is to find out if the combination of acalabrutinib and high frequency low dose subcutaneous rituximab is safe and effective in patients who have previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Location: University of Rochester Medical Center
Study Reference #: ULYM18086

Lead Researcher (Principal Investigator)

Lead Researcher: Paul Barr

Study Contact Information

Study Coordinator: Lauren Mitchell
Email: lauren_mitchell@urmc.rochester.edu

Additional Study Details

Contact This Study

First Name *

This field is required

Middle Name

Last Name *

This field is required

Phone Number

I agree to be contacted by The University of Rochester Medical Center regarding participation in this study. *

You must agree to be contacted to continue.

Please call me during the day.

Please call me during the evening.

Message

Return to Search

Wilmot Research